What advantages does MenAfriVac have over existing polysaccharide meningococcal vaccines currently used to combat epidemics in Africa?
Contrary to polysaccharide vaccines that are used currently to control epidemics after they have begun, the new conjugate vaccine will be offered to prevent epidemics. Key advantages of the new vaccine over existing polysaccharide vaccines are: ??it induces a higher and more sustainable immune response against the most prominent strain in the most affected age groups, from 1-29 years; ?it is expected to confer long-term protection not only for those who receive the vaccine, but on family members and others who would otherwise have been exposed to meningitis, given reduced transmission: ??it will be available at a lower price than other meningococcal vaccines, and significantly lower than other cutting-edge vaccines recently introduced in Africa; and ??it is expected to be particularly effective in protecting children under two years of age, who do not respond to conventional polysaccharide vaccines.